Oncternal Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Oncternal TherapeuticsDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 82.4% bzw. 29.5% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich um 11% pro Jahr wachsen wird.

Wichtige Informationen

-29.5%

Wachstumsrate der Gewinne

11.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	-82.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Mar 03

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Nov 06

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Jul 12

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Jan 12

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Oncternal Therapeutics begins phase 3 study of zilovertamab

Sep 27

Oncternal Therapeutics: Selling For Under Cash Value

Sep 02

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug 09

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09

Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company

Oct 10

Oncternal: Solid Data In 2 Cancers With High Unmet Need

Jun 17

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05

Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Mar 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ONCT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	1	-49	N/A	N/A	1
12/31/2024	2	-35	N/A	N/A	2
9/30/2024	2	-35	-27	-27	N/A
6/30/2024	2	-36	-25	-25	N/A
3/31/2024	1	-36	-29	-29	N/A
12/31/2023	1	-39	-32	-32	N/A
9/30/2023	1	-42	-35	-35	N/A
6/30/2023	1	-43	-41	-41	N/A
3/31/2023	1	-46	-39	-39	N/A
12/31/2022	1	-44	-37	-37	N/A
9/30/2022	2	-41	-34	-34	N/A
6/30/2022	4	-39	-29	-29	N/A
3/31/2022	4	-35	-29	-29	N/A
12/31/2021	4	-31	-27	-27	N/A
9/30/2021	5	-26	-24	-24	N/A
6/30/2021	4	-21	-23	-23	N/A
3/31/2021	4	-18	-19	-19	N/A
12/31/2020	3	-17	-17	-17	N/A
9/30/2020	3	-19	-17	-17	N/A
6/30/2020	2	-19	-15	-15	N/A
3/31/2020	3	-37	-17	-17	N/A
12/31/2019	2	-34	-17	-17	N/A
9/30/2019	2	-31	-16	-16	N/A
6/30/2019	2	-28	-12	-12	N/A
3/31/2019	3	-7	-7	-7	N/A
12/31/2018	3	-7	-7	-7	N/A
12/31/2017	2	-10	N/A	-9	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ONCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ONCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ONCT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ONCTDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-82.4% pro Jahr).

Hohe Wachstumseinnahmen: ONCTDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-82.4% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ONCT in 3 Jahren voraussichtlich hoch sein wird

Oncternal Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 9.8% to US$27.67

Consensus estimates of losses per share improve by 10%

Consensus EPS estimates fall by 12%

Consensus revenue estimates fall by 25%

Price target decreased by 8.5% to US$39.67

Consensus revenue estimates increase by 13%

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Oncternal Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Oncternal Therapeutics, Inc. Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Price target decreased by 9.8% to US$27.67

Consensus estimates of losses per share improve by 10%

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Consensus EPS estimates fall by 12%

Oncternal Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates fall by 25%

Non-Independent Director recently bought US$59k worth of stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Oncternal Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science

Price target decreased by 8.5% to US$39.67

Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq’s Minimum Bid Price Requirement

Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Consensus revenue estimates increase by 13%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board

New major risk - Financial position

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Nasdaq Grants Oncternal Therapeutics an Additional 180 Calendar Days, or to April 1, 2024, to Regain Compliance with the Minimum Bid Requirement

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 26%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncternal Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

Oncternal Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates decrease by 26%, EPS upgraded

Consensus revenue estimates increase by 11%

Consensus revenue estimates fall by 30%

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics, Inc. Appoints Jill DeSimone to the Board of Directors

Oncternal Therapeutics, Inc. Announces the Resignation of Jinzhu Chen from the Board of Directors

Oncternal Therapeutics, Inc. Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib

Price target decreased to US$9.42

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 loss in 3Q 2021)

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

Oncternal Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oncternal Therapeutics, Inc Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

Oncternal Therapeutics begins phase 3 study of zilovertamab

Oncternal Therapeutics: Selling For Under Cash Value

Oncternal Therapeutics, Inc. Submitted an Investigational New Drug Application (“IND”) for ONCT-808

Consensus forecasts updated

Price target decreased to US$9.42

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

High number of new directors

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in Combination with Ibrutinib for Patients with MCL

Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Oncternal Therapeutics, Inc. Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve